We are live on ! Find out more
NTUS

Natus Medical Inc

Delisted

NTUS was delisted on the 20th of July, 2022.

186 hedge funds and large institutions have $1.05B invested in Natus Medical Inc in 2022 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 42 increasing their positions, 72 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 35

24% more capital invested

Capital invested by funds: $847M → $1.05B (+$205M)

8% more funds holding

Funds holding: 172186 (+14)

42% less repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 72

50% less call options, than puts

Call options by funds: $528K | Put options by funds: $1.05M

Holders
186
Holders Change
+14
Holders Change %
+8.14%
% of All Funds
3.13%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
54
Increased
42
Reduced
72
Closed
35
Calls
$528K
Puts
$1.05M
Net Calls
-$526K
Net Calls Change
-$547K
Name Holding Trade Value Shares
Change
Change in
Stake
NAM
26
Nexpoint Asset Management
Texas
$8.57M +$8.27M +261,591 New
CCM
27
Chicago Capital Management
Illinois
$8.24M +$7.95M +251,556 New
Arrowstreet Capital
28
Arrowstreet Capital
Massachusetts
$7.33M -$2M -63,178 -22%
Principal Financial Group
29
Principal Financial Group
Iowa
$7.05M -$701K -22,186 -9%
Invesco
30
Invesco
Georgia
$6.64M -$87.6K -2,772 -1%
KLC
31
Kent Lake Capital
Nevada
$6.55M -$474K -15,000 -7%
HSBC Holdings
32
HSBC Holdings
United Kingdom
$6.29M +$5.74M +181,661 +1,824%
SCM
33
Sio Capital Management
New York
$6.26M -$19.2K -608 -0.3%
Barclays
34
Barclays
United Kingdom
$6.18M +$5.09M +161,117 +586%
AA
35
AQR Arbitrage
Connecticut
$5.88M +$5.67M +179,319 New
Qube Research & Technologies (QRT)
36
Qube Research & Technologies (QRT)
United Kingdom
$5.75M +$5.54M +175,426 New
CIM
37
Confluence Investment Management
Missouri
$5.47M -$952K -30,130 -15%
SPF
38
Steven Patrick Farmer
$5.47M +$5.28M +167,040 New
Marshall Wace
39
Marshall Wace
United Kingdom
$5.46M +$5.27M +166,756 New
Ameriprise
40
Ameriprise
Minnesota
$5.45M -$30.2M -954,704 -85%
EFI
41
EHP Funds Inc
Canada
$5.35M +$5.16M +163,151 New
AllianceBernstein
42
AllianceBernstein
Tennessee
$5.2M -$85K -2,688 -2%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
43
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$4.78M +$4.6M +145,700 New
DCM
44
DAFNA Capital Management
California
$4.71M -$1.49M -47,035 -25%
Bank of America
45
Bank of America
North Carolina
$4.2M -$1.12M -35,534 -22%
Russell Investments Group
46
Russell Investments Group
United Kingdom
$3.98M -$1.99M -62,957 -34%
GF
47
Gabelli Funds
New York
$3.96M +$3.81M +120,682 New
RA
48
Royce & Associates
New York
$3.95M -$7.6M -240,401 -67%
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$3.92M +$526K +16,648 +16%
Citigroup
50
Citigroup
New York
$3.85M +$2.67M +84,628 +258%

NTUS Hedge Fund Activity: Q2 2022 in Review

186 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Natus Medical Inc (NTUS) for Q2 2022, worth a combined $1.05B — up 24% from $847M a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new NTUS positions and 35 closed out — a net gain of 19 holders — while 42 added to existing stakes and 72 trimmed.

The largest buyer was Melqart Asset Management, opening a new position worth an estimated $24.1M. The largest seller was Ameriprise, cutting an estimated $30.2M.

  • 186 institutional investors held Natus Medical Inc (NTUS) as of Q2 2022, up from 172 in Q1 2022.
  • Funds reported $1.05B of Natus Medical Inc stock for Q2 2022, up 24% quarter-over-quarter.
  • 54 funds opened new Natus Medical Inc positions in Q2 2022 and 35 closed out, a net change of +19 holders.
  • The largest Natus Medical Inc buyer in Q2 2022 was Melqart Asset Management, an estimated $24.1M added.
  • The largest Natus Medical Inc seller in Q2 2022 was Ameriprise, an estimated $30.2M sold.

Based on aggregated 13F filings for Q2 2022.